Natera (NASDAQ:NTRA) Downgraded to “Hold” at Zacks Investment Research
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
NTRA has been the topic of a number of other reports. Piper Jaffray Companies set a $40.00 price target on shares of Tapestry and gave the company a buy rating in a research report on Monday, June 10th. Canaccord Genuity reiterated an average rating on shares of Kellogg in a research report on Tuesday, June 25th. Finally, BidaskClub cut shares of Virtu Financial from a sell rating to a strong sell rating in a research report on Wednesday, June 12th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $30.14.
Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. The business had revenue of $66.82 million for the quarter, compared to analysts’ expectations of $66.40 million. On average, equities analysts predict that Natera will post -2.17 EPS for the current fiscal year.
In other news, Chairman Matthew Rabinowitz sold 1,418 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total value of $35,152.22. Following the transaction, the chairman now owns 1,286,612 shares in the company, valued at $31,895,111.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $24.79, for a total transaction of $25,608.07. Following the completion of the transaction, the insider now owns 240,061 shares in the company, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. Insiders sold 5,771 shares of company stock worth $140,742 in the last 90 days. Company insiders own 9.29% of the company’s stock.
Several institutional investors have recently modified their holdings of NTRA. Great West Life Assurance Co. Can grew its holdings in shares of Natera by 136.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after purchasing an additional 3,420 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Natera by 827.1% in the first quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock worth $163,000 after purchasing an additional 7,047 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Natera by 431.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock worth $166,000 after purchasing an additional 9,636 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Natera in the first quarter worth approximately $264,000. Hedge funds and other institutional investors own 80.27% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Understanding Analyst Recommendations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.